Your browser doesn't support javascript.
loading
Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells.
Tominaga, K; Shimamura, T; Kimura, N; Murayama, T; Matsubara, D; Kanauchi, H; Niida, A; Shimizu, S; Nishioka, K; Tsuji, E-I; Yano, M; Sugano, S; Shimono, Y; Ishii, H; Saya, H; Mori, M; Akashi, K; Tada, K-I; Ogawa, T; Tojo, A; Miyano, S; Gotoh, N.
Affiliation
  • Tominaga K; Division of Molecular Therapy, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
  • Shimamura T; Fellow of the Japan Society for the Promotion of Science (JSPS), Tokyo, Japan.
  • Kimura N; Laboratory of DNA information Analysis, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
  • Murayama T; Division of Molecular Therapy, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
  • Matsubara D; Division of Molecular Therapy, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
  • Kanauchi H; Division of Cancer Cell Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
  • Niida A; Laboratory of Functional Genomics, Department of Medical Genome Sciences, Graduate School of Frontier Science, University of Tokyo, Minato-ku, Tokyo, Japan.
  • Shimizu S; Division of Molecular Pathology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
  • Nishioka K; Department of Breast and Endocrine Surgery, Showa General Hospital, Kodaira, Tokyo, Japan.
  • Tsuji EI; Laboratory of DNA information Analysis, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
  • Yano M; Department of Pathological Diagnosis, Showa General Hospital, Kodaira, Tokyo, Japan.
  • Sugano S; Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
  • Shimono Y; Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
  • Ishii H; Department of Surgery, Minami machida Hospital, Machida, Tokyo, Japan.
  • Saya H; Laboratory of Functional Genomics, Department of Medical Genome Sciences, Graduate School of Frontier Science, University of Tokyo, Minato-ku, Tokyo, Japan.
  • Mori M; Division of Molecular and Cellular Biology, Kobe University, Graduate School of Medicine, Kobe, Japan.
  • Akashi K; Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Tada KI; Division of Gene Regulation, Institute of Advanced Medical Research, Graduate School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan.
  • Ogawa T; Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Tojo A; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan.
  • Miyano S; Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
  • Gotoh N; Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Oncogene ; 36(9): 1276-1286, 2017 03 02.
Article in En | MEDLINE | ID: mdl-27546618
ABSTRACT
The transcription factor nuclear factor-κB (NF-κB) has important roles for tumorigenesis, but how it regulates cancer stem cells (CSCs) remains largely unclear. We identified insulin-like growth factor 2 (IGF2) is a key target of NF-κB activated by HER2/HER3 signaling to form tumor spheres in breast cancer cells. The IGF2 receptor, IGF1 R, was expressed at high levels in CSC-enriched populations in primary breast cancer cells. Moreover, IGF2-PI3K (IGF2-phosphatidyl inositol 3 kinase) signaling induced expression of a stemness transcription factor, inhibitor of DNA-binding 1 (ID1), and IGF2 itself. ID1 knockdown greatly reduced IGF2 expression, and tumor sphere formation. Finally, treatment with anti-IGF1/2 antibodies blocked tumorigenesis derived from the IGF1Rhigh CSC-enriched population in a patient-derived xenograft model. Thus, NF-κB may trigger IGF2-ID1-IGF2-positive feedback circuits that allow cancer stem-like cells to appear. Then, they may become addicted to the circuits. As the circuits are the Achilles' heels of CSCs, it will be critical to break them for eradication of CSCs.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplastic Stem Cells / Breast Neoplasms / Insulin-Like Growth Factor II / Gene Expression Regulation, Neoplastic / Inhibitor of Differentiation Protein 1 / Neoplasm Recurrence, Local Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2017 Document type: Article Affiliation country: Japón

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplastic Stem Cells / Breast Neoplasms / Insulin-Like Growth Factor II / Gene Expression Regulation, Neoplastic / Inhibitor of Differentiation Protein 1 / Neoplasm Recurrence, Local Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2017 Document type: Article Affiliation country: Japón